Add BrightSurf on Google Email

The Lancet


Use of animals in medical research

The Lancet's editorial advocates for animal research to improve human health and develop new medicines, despite potential controversy. The journal emphasizes the need for scientific justification and responsible animal care in experiments.

SourceThe Lancet_DELETED·JournalThe Lancet·DateSep 2, 2004

Does the Atkins diet actually work?

A rapid review of the Atkins diet suggests that it can lead to significant weight loss in the short-term, with individuals on the low-carbohydrate diet losing more weight than those on an energy-restricted low-fat diet. However, long-term effects and potential health risks remain uncertain, highlighting the need for further research.

SourceThe Lancet_DELETED·JournalThe Lancet·DateSep 2, 2004

Study highlights long-term efficacy of angina drug

A new study highlights the long-term efficacy and safety of the angina drug nifedipine GITS, showing it can be used safely for the treatment of patients with coronary disease. The trial found similar mortality rates among those receiving the medication and a placebo, but lower incidence of heart failure and coronary interventions.

SourceThe Lancet_DELETED·JournalThe Lancet·DateAug 30, 2004

Paediatric research should take centre stage

Paediatric research is crucial for disease prevention and treatment, yet data are lacking due to a lack of legislation requiring companies to conduct trials on children. The UK Government's new initiative aims to invest £100 million in research networks but falls short of centre stage for acquiring research-based evidence.

SourceThe Lancet_DELETED·JournalThe Lancet·DateAug 26, 2004

More doctors needed, without discrimination

The number of female consultants has risen by more than 50% in the last 10 years, driven by increasing numbers of women admitted to medical school. However, sexism and a lack of flexibility in working environments are still major issues affecting female doctors' careers.

SourceThe Lancet_DELETED·JournalThe Lancet·DateAug 12, 2004

COPD—A neglected disease

Chronic obstructive pulmonary disease (COPD) is characterized by progressive lung damage and increased mortality worldwide. The five-article series aims to increase awareness of COPD through advances in understanding and management.

SourceThe Lancet_DELETED·JournalThe Lancet·DateAug 12, 2004

Spiders or scapegoats

A study challenges the common perception that spiders cause many diseases, including skin ulcers and flesh-eating skin disease. In reality, spider bites are rare and generally harmless, while other causes of these conditions are more likely.

SourceThe Lancet_DELETED·JournalThe Lancet·DateAug 5, 2004

The practicalities of keeping clean

The Lancet editorial highlights concerns about the practicality of implementing government plans for cleaner hospitals and lower rates of infection. Key issues include a lack of resources and clear timetable for implementation, as well as insufficient sanctions for hospitals that fail to maintain acceptable levels of cleanliness.

SourceThe Lancet_DELETED·JournalThe Lancet·DateJul 22, 2004

Could skin cells become brain cells?

Researchers have successfully generated nerve precursor cells from adult skin cells using a two-step process involving soluble agents called growth factors. This breakthrough raises the possibility of generating nerve cells from an individual's own skin cells, overcoming issues of rejection.

SourceThe Lancet_DELETED·JournalThe Lancet·DateJul 8, 2004

HIV/AIDS issue: July 3, 2004

The Lancet discusses new design changes to the journal, including open-access policies and electronic document posting. The article also explores various HIV/AIDS strategies for developing countries, including expanded access to treatment and prevention efforts. Researchers emphasize the importance of local solutions and community-led ...

SourceThe Lancet_DELETED·JournalThe Lancet·DateJul 1, 2004

Call for removal of Crestor

Rosuvastatin, marketed as Crestor, has been linked to a higher incidence of rhabdomyolysis and renal insufficiency compared to other statins. The drug's manufacturer, AstraZeneca, is estimated to be seeking $20 billion in annual sales, making it morally unjustifiable to keep the drug on the market.

SourceThe Lancet_DELETED·JournalThe Lancet·DateJun 24, 2004